[The formation of clinical and functional remission during the treatment of non-psychotic depression with escitalopram (lenuxin)].

The results of this study showed a high frequency of clinical remission (45.26%) during therapy of 98 patients with non-psychotic depression with escitalopram (lenuxin). However, the majority of patients (81.4%) had symptomatic remission presented with persistent isolated monosymptom of insomnia, anxiety, somatic-autonomic disorders or hypochondria spectrum. The complete recovery of social functioning (functional remission) in all areas (work, communication, family) was observed in 51.16% patients. The relationship between the severity of residual symptoms and functional remission justifies the need to include clinical and subjective indicators in a modern integrative concept of remission. The high efficacy of escitalopram (lenuxin) was combined with its favorable tolerability profile.